# Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

> **NCT04008511** · PHASE1,PHASE2 · UNKNOWN · sponsor: **China Medical University, China** · enrollment: 54 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Regorafenib
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT04008511
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07
- **Primary completion:** 2023-03
- **Final completion:** 2024-03
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2019-07-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04008511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04008511, "Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04008511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*